D-dimer Testing Market

1
D-dimer Testing Market to hit USD 2 Bn by 2032,
says Global Market Insights Inc.
2

• D-Dimer Testing Market size is predicted to
  register over USD 2 billion by 2032. The
  increasing prevalence of conditions, such as deep
  vein thrombosis (DVT), pulmonary embolism (PE),
  and disseminated intravascular coagulation (DIC)
  will drive the industry progression.
• Request for a sample of this research report
  _at_ https//www.gminsights.com/request-sample/detail
  /5972
• As per the Centre of Disease Control and
  Prevention (CDC), the number of individuals
  annually impacted by deep vein thrombosis (DVT)
  or pulmonary embolism (PE) reached 900,000 people
  in the U.S. These conditions often necessitate
  D-Dimer testing as part of the diagnostic process
  to assess the likelihood of thrombotic events.
  The rising aging population, associated with
  obesity and sedentary habits, is also
  contributing to the growing incidence of
  thrombotic disorders.
• Rising advancements in healthcare infrastructure,
  particularly in emerging economies, are boosting
  accessibility to diagnostic services, including
  D-Dimer testing. There is a growing awareness
  among healthcare professionals about the utility
  of this testing in diagnosing thrombotic
  disorders at an early stage. The integration of
  novel technologies, such as point-of-care testing
  and automation in laboratory settings to enhance
  the efficiency and accuracy of D-Dimer assays
  will add to the market gains.

3

• Rising usage to treat pulmonary embolism
• D-Dimer testing market from the pulmonary
  embolism (PE) application segment is slated to
  record high demand by 2032, as it represents a
  life-threatening condition characterized by the
  blockage of arteries in the lungs, often
  resulting from blood clots originating in other
  body parts. D-Dimer testing helps in the
  assessment of suspected cases of pulmonary
  embolism, aiding clinicians in ruling out or
  confirming the presence of thrombotic events. The
  rising incidence of prolonged immobility,
  surgery, and certain medical conditions will also
  contribute to the increased demand for PE
  diagnosis.
• Growing presence in hospitals
• The hospitals segment in the D-dimer testing
  market is poised to generate notable revenues
  during 2024 and 2032, due to their higher
  popularity as primary hubs for patient care,
  diagnosis, and treatment. With rising burden of
  thrombotic disorders globally, hospitals witness
  a steady influx of patients with symptoms like
  deep vein thrombosis (DVT) and pulmonary
  embolism. Hospitals also often house advanced
  laboratory facilities equipped with automated
  testing platforms and skilled personnel for
  facilitating efficient and high-throughput
  D-Dimer testing.

4
Asia Pacific to emerge as a lucrative market The
Asia Pacific D-dimer testing market is touted to
surge at a rapid pace from 2024 to 2032,
attributed to the increasing adoption of western
lifestyle habits coupled with rising urbanization
and sedentary lifestyles. The expanding geriatric
population across Asia Pacific countries,
particularly in Japan, China, and India, is
predisposed to a higher incidence of thrombotic
events. The improving healthcare infrastructure
and growing investments in medical RD activities
in countries like South Korea and Singapore are
facilitating greater accessibility to advanced
diagnostic technologies.   Request for Report
Customization _at_ https//www.gminsights.com/roc/597
2   D-Dimer Testing Industry Participants Some
major companies in the global D-Dimer testing
market include Siemens Healthcare GmbH, Abbott
Laboratories, Thermo Fisher Scientific Inc.,
BioMedica Diagnostics, Unbound Medicine Inc
biomérieux SA, Quidel Corporation, Diazyme
Laboratories Inc. (General Atomics), FHoffmann-La
Roche Ltd., HORIBA Ltd., Sekisui Diagnostics LLC
(Sekisui Chemical Co. Ltd.), and Werfen. These
firms are focusing on partnership ventures to
widen their global presence and customer base.
For instance, in May 2022, the assay, developed
by Horiba Medical, successfully detected venous
thromboembolism (VTE) with excellent accuracy,
reliability, and turnaround time on the
manufacturer's Yumizen G800 fully automated
hemostasis analyzer.